VIMOVO

Land: Israel

Sprache: Englisch

Quelle: Ministry of Health

Wirkstoff:

ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE 20 MG; NAPROXEN 500 MG

Verfügbar ab:

ASTRA ZENECA ISRAEL LTD

ATC-Code:

G02CC02

Darreichungsform:

TABLETS MODIFIED RELEASE

Verabreichungsweg:

PER OS

Hergestellt von:

ASTRA ZENECA AB., SWEDEN

Therapiegruppe:

NAPROXEN

Anwendungsgebiete:

Vimovo is a combination product that contains naproxen and esomeprazole. It is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.Vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.

Berechtigungsdatum:

2011-12-01